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Abstract 
There is increasing evidence showing that brain atrophy varies between patients with 
Alzheimer’s disease (AD), suggesting that different anatomical patterns might exist 
within the same disorder. We investigated AD heterogeneity based on cortical and 
subcortical atrophy patterns in 299 AD subjects from two multicenter cohorts. 
Clusters of patients and important discriminative features were determined using 
random forest pairwise similarity, multidimensional scaling and distance-based 
hierarchical clustering. We discovered two typical (72.2%) and three atypical (28.8%) 
subtypes with significantly different demographic, clinical and cognitive 
characteristics, and different rates of cognitive decline. In contrast to previous studies, 
our unsupervised random forest approach based on cortical and subcortical volume 
measures and their linear and non-linear interactions, revealed more typical AD 
subtypes with important anatomically discriminative features, while the prevalence of 
atypical cases was lower. The hippocampal-sparing and typical AD subtypes, 
exhibited worse clinical progression in visuospatial, memory and executive cognitive 
functions. Our findings suggest there is substantial heterogeneity in AD that has an 
impact on how patients function and progress over time.   
 
Keywords: Alzheimer's disease; structural magnetic resonance imaging; cortical 
volumes; subcortical volumes; cluster analyses; Random forest similarity. 
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1. Introduction 
Alzheimer’s disease (AD) is a progressive and ultimately fatal neurodegenerative 
disorder characterized by loss of memory and other cognitive functions (Frisoni et al., 
2010). The pathological hallmarks of AD consist of aggregation of β-amyloid (Aβ) 
peptides into plaques and phosphorylation of tau into neurofibrillary tangles (Shaw et 
al., 2009), which are thought to spread in the brain in an orderly fashion (Braak and 
Braak, 1991). For instance, neurofibrillary tangles first appear in the entorhinal cortex 
and hippocampus, then spread to neocortical association areas and finally reach the 
primary cortex. However, recent evidence suggests that many patients with AD do not 
show this spatial pattern of progression of tangles, indicating that there might be 
distinct pathological subtypes within AD.  
In a previous neuropathological study, Murray et al. (2011) found three distinct AD 
pathological subtypes based on the distribution of tangles in the brain. These subtypes 
were characterized by either a high number of neurofibrillary tangles in the 
hippocampus, cortical regions or both and were labeled as limbic-predominant, 
hippocampal-sparing and typical, respectively. Followed by this description of 
subtypes, Whitwell et al. (2012) investigated the gray matter differences on structural 
MRI between these pathological groups and found an association between 
neurofibrillary tangle deposition and brain atrophy. In addition, the fact that gray 
matter changes mirrored the regional distribution of tangles suggests that the different 
pathological subtypes of AD can be investigated in vivo using structural 
neuroimaging. 
Up to date, two main classes of approaches have been applied to assess the 
neuroanatomical heterogeneity in AD. The first class consists of identifying different 
AD subtypes using a supervised approach based on prior clinical, pathological or 
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neuroimaging criteria, followed by univariate statistical analysis to define distinct 
anatomical patterns (Whitwell et al., 2012; Byun et al., 2015; Ferreira et al., 2017). 
These methods do not allow exploring the variability within the AD population in an 
unsupervised, unbiased way with respect to its neuroanatomical properties. Moreover, 
univariate analyses do not consider interactions between variables. 
The second class of approaches for the identification of AD subtypes includes 
unsupervised learning methods such as clustering (Noh et al., 1014; Dong et al., 2016; 
Hwang et al., 2016; Zhang et al., 2016; Park et al., 2017) and semi-supervised (Varol 
et al., 2017) multivariate methods using voxel-based or surface-based morphometry 
measures. These studies found diverse clusters of atrophy that were partially similar 
to the ones previously reported in the literature (Murray et al., 2011; Whitwell et al., 
2012). However, in some studies (Noh et al., 1014; Hwang et al., 2016), the cluster 
analyses were carried out on a large number of anatomical measures (78,570 cortical 
thickness vertices) in relatively small groups of AD patients (152 and 77 patients 
respectively). Carrying out cluster analyses in such high-dimensional datasets of 
anatomical measures when only small samples of subjects are available can make the 
distance measures improper to distinguish different groups (Parsons et al., 2004). 
Moreover, two studies assessed how different subtypes of brain atrophy affected 
clinical progression in AD (Dong et al., 2016; Na et al., 2016). The first study used 
both MCI and AD patients in their clustering analyses, which could have influenced 
the identification of subtypes since not all MCI patients convert to AD (Dong et al., 
2016). The second study (Na et al., 2016) assessed the clinical progression of 
previously defined subtypes (Noh et al., 2014) that we discussed above and it is 
important to remark that the cluster analysis was based only on cortical thickness 
measures and did not include subcortical brain structures as in Park et al. (2017). 
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Hence, to address these limitations, in this study we performed cluster analyses on the 
gray matter volumes of 162 cortical and subcortical regions of interest (ROI) in 299 
AD patients. We applied the Random forest method since it accounts for linear and 
non-linear interactions between brain regions, which have only been considered in 
one previous study (Varol et al., 2017). Moreover, in our analyses we did not make 
any prior assumptions on the number of subtypes or their anatomical patterns in order 
to avoid inference and interpretation limitations. After defining clusters of brain 
atrophy, we compared the clinical characteristics between different AD subtypes at 
baseline and after one year. In addition, we assessed the ability of the hippocampus to 
cortex volume ratio in discriminating AD groups to evaluate its utility as a marker of 
heterogeneity in AD, as was suggest by Whitwell et al. (2012). We hypothesized that 
similar patterns of brain atrophy would be found compared to those described in 
previous neuropathological studies (Murray et al., 2011; Whitwell et al., 2012). 
Moreover, we also predicted that these patterns would be associated with distinct 
cognitive profiles, highlighting the clinical relevance of studying the heterogeneity 
present in AD. 
 
2. Materials and methods 
2.1. Subjects 
The dataset used in this study was obtained from two large multicentre cohorts, the 
AddNeuroMed and the Alzheimer's disease Neuroimaging Initiative (ADNI). 
AddNeuroMed is an integrated project that is part of InnoMed (the Innovative 
Medicines Initiative) and funded by the European Union Sixth Framework program 
(Lovestone et al., 2007, 2009). The main objective of AddNeuroMed is to identify 
biomarkers or experimental models that can improve diagnosis, prediction and 
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monitoring of disease progression in AD. Regarding neuroimaging, AddNeuroMed 
uses magnetic resonance imaging (MRI) and magnetic resonance spectoscopy (MRS) 
to extract valuable information for the identification of AD biomarkers (Westman et 
al., 2011). The MRI data for AddNeuroMed was collected from different centres 
across Europe (Lovestone et al., 2009; Simmons et al., 2009, 2011): University of 
Perugia (Italy), King's College London (United Kingdom), Aristotle University of 
Thessaloniki (Greece), University of Kuopio (Finland), University of Lodz (Poland) 
and University of Toulouse (France). AD patients were recruited from the memory 
clinics of each of the six participant sites using the following inclusion criteria: 1) 
fulfilling with the ADRDA/NINCDS for probable AD and DSM-IV criteria for 
dementia AD; 2) mini-mental state examination (MMSE) score between 12 and 28; 3) 
age 65 years or above. Exclusion criteria for AD patients consisted of any major 
unstable systematic organ failure, and significant psychiatric or neurological diseases 
apart from AD. Controls from AddNeuroMed were recruited from social centers for 
the elderly or GP surgeries, caregiver's or unrelated family relatives using the 
following inclusion criteria: 1) MMSE score between 24 and 30; 2) age 65 years or 
above; 3) geriatric depression scale equal to or less than 5; 4) stable medication; 5) 
good general health; 6) a clinical dementia rating (CDR) score of zero. Exclusion 
criteria for controls consisted of fulfilling criteria for dementia (DSM- IV), significant 
neurological, psychiatric or unstable systematic illness and organ failure. 
The ADNI was launched in 2003 as a public–private partnership, led by Principal 
Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 
whether serial MRI, PET, other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI 
and early AD. Similarly to the AddNeuroMed study, ADNI strives to reveal sensitive 
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and specific markers of AD progression in patients from various sites to support the 
development of new treatments and monitor their effectiveness, as well as to reduce 
the expenditures of clinical trials. The inclusion criteria for AD patients from ADNI 
were the following: 1) fulfilling the NINCDS/ADRDA criteria for probable AD; 2) 
MMSE score between 20 and 26; 3) CDR score of 0.5 or 1.0. Exclusion criteria 
comprised history of structural brain lesions or head trauma, significant neurological 
disease other than incipient AD, and the use of psychotropic medications that could 
affect memory. The inclusion criteria for controls were: 1) MMSE between 24 and 
30; 2) CDR score equal to zero. Presence of depression, mild cognitive impairment 
and dementia were used as exclusion criteria for this group. For more information on 
the ADNI study, see www.adni-info.org.  
Informed consent was obtained from all subjects included in this study. For AD 
patients, consent was obtained both from the patient and a relative. In the 
AddNeuroMed cohort, the Alzheimer's disease assessment scale (ADAS) was 
substituted by the CERAD cognitive battery to assess cognitive functions in controls. 
The only comparable measure between CERAD (The Consortium to Establish a 
Registry for Alzheimer’s Disease) and ADAS cognitive batteries is the word recall 
task (Westman et al., 2011). Therefore the comparison between AD subtypes and 
controls regarding the ADAS subtests is limited to the word recall subtest. 
 
2.2. MRI acquisition 
The MRI data from ADNI and AddNeuroMed were acquired using the same protocol 
(Jack et al., 2008), which consisted of a high-resolution sagittal 3D T1-weighted 
MPRAGE volume (voxel size 1.1×1.1×1.2 mm3) (Westman et al., 2011). Full brain 
and scull coverage was required for both cohorts, and image quality control took 
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place according to the AddNeuroMed’s quality control procedure (Simmons et al., 
2009, 2011). Similarly to previous studies (Pereira et al., 2016; Spulber et al. 2013; 
Falahati et al. 2016), the data from both cohorts were combined since they show 
similar patterns of atrophy and predictive power in discriminating AD and MCI 
patients from controls (Westman et al. 2011). 
 
2.3. MRI preprocessing 
T1-weighted images were preprocessed using FreeSurfer (version 5.3; 
http://freesurfer.net/), which provides cortical and subcortical measures of gray matter 
volume that can be used for statistical analyses. All data was preprocessed through the 
HiveDB database system (Muehlboeck et al., 2008). The FreeSurfer preprocessing 
stream consists of several steps: correction of motion artefacts and spatial distortions; 
removal of non-brain tissue (Segonne et al., 2004); transformation to the Talairach 
standard space; intensity normalization (Sled et al., 1998) segmentation of subcortical 
white matter and deep gray matter structures; tessellation of the gray/white matter 
boundary; automated topology correction (Segonne et al., 2007); and surface 
deformation to place the gray/white and gray/CSF borders (Fischl and Dale, 2000). 
Once the cortical models were complete, registration to a spherical atlas took place, 
which utilizes individual cortical folding patterns to match cortical geometry across 
subjects (Fischl et al., 1999). This was followed by parcellation of the cerebral cortex 
into 148 cortical regions (Destrieux et al., 2010). In this study, we extracted the 
volumes from these cortical regions in addition to seven gray matter subcortical 
structures for each hemisphere: hippocampus, amygdala, thalamus, caudate, putamen, 
accumbens and pallidum (Fischl et al., 2002). We also obtained the estimated total 
intracranial volume (ICV), an indirect measure of head size, from FreeSurfer 
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(Buckner et al., 2004). In this study we used volume measures because they are 
available for cortical and subcortical regions in contrast to cortical thickness, which is 
not available for subcortical structures in FreeSurfer. 
 
2.4. Cluster analyses 
In total, 162 volume measures (148 cortical and 14 subcortical) (Supplementary Table 
1 and 2) were included in the cluster analyses to assess different patterns of brain 
atrophy in AD patients. To correct these volume measures for head size, we applied a 
residual approach using previously established methods (O’Brien et al., 2006; 
Voevodskaya et al., 2014). The adjusted volumes were obtained as follows: 
	 =  −  − ICV,	 
where 	  is the ICV-adjusted volume of interest (VOI),   is the 
original uncorrected VOI, 	 is the slope calculated from the linear regression of 
 of each brain region to the  in controls,  is the subject’s ICV, and  
  is the mean ICV across all subjects. We performed cluster analyses on the 
adjusted 162 regional volumes of AD patients from ADNI and AddNeuroMed using 
the random forest method (Breiman, 2001) implemented in R (The R Foundation for 
Statistical Computing; version 3.2.3). The random forest method is an ensemble 
classifier consisting of many decision trees (Breiman, 1996), where the final result is 
obtained by combining the predictions of all individual trees. This method combines 
random feature selection (Amit and Geman, 1997) and bootstrap aggregation 
(Breiman, 1996), which is important to prevent data overfitting and increase the 
prediction power.  
The random forest architecture allows the computation of a similarity (proximity) 
measure between pairs of observations (Shi and Horvath, 2006). If we assume 
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observations i and j, their similarity measure   initializes in zero. Each tree then 
decides to assign observations together on a certain class by directing them on the 
same terminal node. Each time the pair i and j end up on the same terminal node, the 
similarity measure  increases by one. At the end of the process, the similarities are 
symmetrized and divided by the number of trees. If a dataset has N observations, the 
resulting pairwise similarity matrix consists by N*N elements. We chose to use the 
random forest similarity measure instead of a conventional distance measure (e.g. 
Euclidean) due to the following reasons: a) it carries information regarding the linear 
and nonlinear interactions of the variables under assessment; b) it provides measures 
of variable importance; and c) it carries no cluster distribution assumptions. 
The random forest classifier distinguishes synthetic from observed data if the latter 
has inherent clusters (Shi and Horvath, 2006). As observed data we used the AD 
dataset, while as synthetic data we used a dataset that was drawn from a reference 
distribution such that there is no relationship between observations or variables (Shi 
and Horvath, 2006). The Addcl1 method was used in the current study for 
constructing a synthetic dataset (Shi and Horvath, 2006). Using this method, first we 
randomly sampled one value from the spectrum of observed values in the first 
variable of the dataset. The same process was repeated for all the variables resulting 
in one synthetic observation with in-dependency over variables. A synthetic class was 
defined by combining the observed and synthetic datasets and labeling them as class 1 
and 2, respectively. In order to group patients into clusters, we applied the random 
forest algorithm to the dataset and extracted the similarity matrix. Additionally, we 
applied classical multidimensional scaling (MDS) to the similarity matrix to extract a 
lower dimensional representation of the similarity matrix since the Addcl1 random 
forest similarity performs well in conjunction with the MDS (Shi and Horvath, 2006; 
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Gray et al., 2013). Through that step we were able to visually inspect the pairwise 
similarity of the subjects in the Euclidean space as well as observe which clusters 
were sparse. Finally, we applied an agglomerative hierarchical clustering algorithm 
with average linkage (Gray et al., 2013). This hierarchical clustering method starts by 
assigning every subject to one cluster. The average linkage uses the mean distance 
between elements of each cluster as a criterion for merging two clusters together. The 
algorithm continues merging subjects into clusters until all the subjects form a single 
group. Then, the desirable cut off (number of clusters) can be decided by using a 
clustering evaluation criterion or by inspecting the low dimensional coordinates of the 
data. In this study, we assessed the clustering quality for different number of clusters 
with six indices and finally used the average Hopkins statistic (Banerjee and Dave, 
2004) to decide the cut off value (Supplementary material 2.2). The Hopkins statistic 
assessed clustering tendency where values between 0 and 0.5 reflect heterogeneous 
clusters, values around 0.5 reflect clusters that are homogeneous between themselves, 
and values greater than 0.5 reflect very well defined clusters.  
The random forest algorithm induces perturbations in the subject population by design 
through the bootstrapping feature. Every tree of the forest uses only a subset of the 
data, which consists of 70% of the original dataset randomly chosen (with 
replacement) and then the model is validated in the remaining 30%. To further assess 
the reproducibility of the results, we repeated the random forest 100 times with 
random seeding and computed the average change in the similarity measures. More 
information about the random forest parameterization, its evaluation, reproducibility, 
and the clustering validity can be found in the supplementary material 2.1 and 2.2. 
 
2.5. Supervised analysis 
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After extracting the clusters, a classification decision tree was built (Breiman, 1996) 
using the 10 most important anatomical variables from the random forest analysis. We 
selected 10 variables in order to keep the complexity of the decision tree low and 
increase its interpretability. Additional variables with lower importance could also be 
included but this may introduce overfitting and produce discrimination rules with very 
low confidence for generalization (Müller and Guido, 2017). In this tree, the 
anatomical variables were included as predictors with no scaling (Müller and Guido, 
2017) and the cluster number was included as the dependent variable. In this way, we 
obtained information regarding how the important anatomical features of the random 
forest differed for each subtype. 
 
2.6. Statistical analyses 
To compare the baseline demographic and clinical characteristics between AD 
subtypes, we used   tests for nominal variables and the Kruskal-Wallis test for 
ordinal variables. To assess differences in cognitive variables between baseline and 
follow-up within each AD group, the Wilcoxon rank sum test was used. A Holm-
Šídák correction was used to control for multiple comparisons in all these analyses. 
To calculate the hippocampus to cortex volume ratio, we averaged the left and right 
hippocampus and divided it by the average of three cortical regions (Whitwell et al., 
2012) from the Destrieux atlas: 1) frontal ROI (sum of the bilateral middle frontal 
cortices), 2) parietal ROI (sum of the bilateral inferior parietal cortices), 3) temporal 
ROI (sum of the bilateral superior temporal cortices). 
 
3. Results 
3.1. AD anatomical subtypes  
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The optimal number of clusters for the dataset of 162 anatomical variables in 299 AD 
patients was five, as a function of the average Hopkins statistic (See supplementary 
material 2.2). Figure 1A shows the random forest similarity matrix after 
multidimensional scaling and Figure 1B shows the hierarchical clustering tree. At the 
5-cluster level, patients were assigned into the following groups with respect to their 
cortical and subcortical atrophy patterns: (1) a group with minimal brain atrophy in 
the left entorhinal cortex (minimal atrophy subtype; n= 54; 18.1%), (2) a group with 
atrophy in temporal and limbic areas (limbic-predominant subtype; n=12; 4%), (3) a 
group with atrophy mainly in parietal and frontal areas (hippocampal-sparing subtype; 
n=17; 5.7%), (4) a group with diffuse atrophy in several cortical and subcortical 
regions, except the postcentral, precentral, caudal middle frontal, paracentral areas 
and cuneus (diffuse 1 subtype; n=167; 55.8%) and (5) a group with the most severe 
and widespread brain atrophy in almost all cortical and subcortical regions (diffuse 2 
subtype; n=49; 16.4%). Figure 2 shows these different patterns of brain atrophy 
displayed on the cortical surface in each AD subtype compared to controls, after 
controlling for age, gender, education and estimated total intracranial volume (eTIV). 
The differences between groups in subcortical volumes can be found in Table 1. Since 
two diffuse subtypes were identified in the current study, we compared the patients in 
these two groups to assess their anatomical differences (Supplementary material 3). 
This comparison showed increased brain atrophy in frontal, parietal and temporal 
areas in the diffuse 2 with respect to the diffuse 1 subtype. Using Freesurfer, we 
carried out a vertex-wise analysis (general linear model) to assess whether the MA 
subtype showed cortical thinning after one year of follow up, compared to the CN 
group. No significant results were found. 
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There was a similar proportion of ADNI and AddNeuroMed patients in each cluster 
(table 2) and their cortical atrophy patterns were similar (supplementary material 4). 
The results of the random forest algorithm were similar when applied to ADNI or 
AddNeuroMed cohorts separately (supplementary material 5). 
 
3.2. Demographic and clinical characteristics in AD subtypes 
At baseline, we found that patients with a limbic-predominant or diffuse subtype were 
significantly older compared to the hippocampal-sparing and minimal atrophy groups 
(p < 0.05). In addition, the limbic-predominant subtype had longer disease duration 
and the hippocampal-sparing and minimal atrophy subtypes had a younger age at 
onset of AD compared to the other groups. Education was significantly lower in the 
group with widespread and diffuse atrophy but only when compared to hippocampal-
sparing patients (Table 2). 
Regarding cognitive variables, MMSE scores were significantly lower in the diffuse 1 
subtype compared to minimal atrophy and diffuse 2 groups and in the diffuse 2 
subtype compared to the minimal atrophy group. There were also significant 
differences in CDR, with the minimal atrophy patients showing lower scores 
compared to the other groups (Table 2). 
At one-year follow-up, there was a significant decline in memory (word recall) and 
visuospatial (orientation) functions in the hippocampal-sparing subtype. The diffuse 1 
group also showed worse cognitive performance in executive (following commands) 
and visuospatial (ideational praxis, orientation) functions. The diffuse 2 group showed 
a significant decline in memory (word recognition) and visuospatial functions 
(orientation, ideational praxis). 
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3.3. Hippocampus to cortex volume ratio 
The limbic-predominant and the minimal atrophy subtypes showed similar values of 
cortical volume (Figure 3A), but different values of hippocampal volume (Figure 3B). 
A similar pattern was observed in the diffuse 2 and hippocampal-sparing subtypes, 
which showed similar cortical volumes (Figure 3A), but differed in hippocampal 
volumes (Figure 3B).  
The values of the hippocampus to cortex volume ratio (Figure 3C) provided a good 
separation between the limbic-predominant, hippocampal-sparing and diffuse 
subtypes. However, this ratio was not able to distinguish the minimal-atrophy subtype 
from the two diffuse subtypes. 
Compared to controls, all the AD subtypes had lower hippocampal volume. The 
cortical volume of the minimal atrophy subtype was similar to controls and the 
limbic-predominant subtype had similar cortical values to controls. The hippocampus 
to cortex ratio of the hippocampal-sparing subtype was similar to controls.  
 
3.4. Supervised analysis 
The supervised classification tree (Figure 4) showed that the precuneus was the most 
important region to discriminate AD subtypes. This brain region was on the top of the 
tree and separated two branches of subtypes: one that included the minimal atrophy, 
limbic-predominant and diffuse 1 and the other included the hippocampal-sparing and 
diffuse 2 subtypes. The first branch or group of subtypes had significantly higher 
volume of the precuneus compared to the second branch of subtypes (p < 0.0001, 
after correction for multiple comparisons). In the first branch, the volumes of the 
middle occipital gyri separated the minimal atrophy (high values) from the limbic-
predominant and diffuse 1 subtypes (low values). In the second branch, the volumes 
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of the orbital gyri separated the hippocampal-sparing (high values) from the diffuse 2 
subtype (low values). Other variables such as the superior temporal, precentral and 
superior parietal gyri contributed less to the discrimination of the first branch of 
subtypes. The parietal superior together with the superior occipital gyri were less, but 
still important variables regarding the discrimination of the diffuse 2 from the 
hippocampal-sparing subtypes.  A complete view of the variable discrimination rules 
between subtypes is available through the tree representation of the model (Figure 4).   
 
4. Discussion 
In this study, we assessed the heterogeneity in the patterns of cortical and subcortical 
brain atrophy in AD. Our main findings revealed that AD patients could be divided 
into a minimal atrophy, limbic-predominant, hippocampal-sparing, and two diffuse 
atrophy subtypes. The five groups differed in age, onset of disease, education and 
cognitive functions. In addition, the hippocampal-sparing and diffuse subtypes 
showed worse cognitive performance over time. This suggests that they might be 
more aggressive disease phenotypes compared to the other groups. Altogether, these 
results suggest that, despite being regarded as a single disorder, AD can be 
characterized by different subtypes of brain atrophy, which might determine the 
progression of the disease. 
There is increasing evidence showing that the spread of neurofibrillary tangles in the 
brain do not always conform to the Braak’s staging scheme (Murray et al., 2011), 
which has been widely used to assess brain pathology at autopsy in AD. In particular, 
in a previous study (Murray et al., 2011), it was shown that 25% of AD cases present 
with an atypical pattern of tangles in the brain. This suggests that atypical 
presentations are frequent and should be considered in prospective longitudinal 
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studies. In line with these findings, our results showed that a similar proportion of 
patients (27.8%, n=83) did not present a diffuse pattern of brain atrophy, which is 
usually found at late stages of AD. Among these patients, 4% (n=12) were 
characterized by volume loss in medial temporal and limbic regions, including the 
hippocampus, anterior temporal poles, insula, orbitofrontal and anterior cingulate 
gyri. In addition, 5.7% (n=17) were characterized by atrophy in the parietal cortex, 
superior frontal and posterior temporal regions, with relative sparing of the medial 
temporal cortex and hippocampus. These two subtypes fit well with the description of 
atypical AD presentations shown in previous studies (Whitwell et al., 2012; Noh et 
al., 2012; Hwang et al., 2016), suggesting that structural MRI is a good biomarker to 
assess AD heterogeneity. The frequency of hippocampal-sparing patients we found in 
our study was similar to the one reported in previous studies (Hwang et al., 2016; 
Byun et al., 2015), while the frequency of the limbic predominant was somewhat 
different from previous studies probably to methodological approaches (Hwang et al., 
2016; Byun et al., 2015; Ferreira et al., 2017). Moreover, we also found that 18.1% 
(n=54) of patients had minimal brain atrophy showing volume loss only in the left 
entorhinal region. This finding is in line with three recent studies showing that some 
AD patients do not show significant brain atrophy compared to controls (Byun et al., 
2015; Dong et al., 2017; Ferreira et al., 2017), indicating that there might be a greater 
variability in brain atrophy patterns in AD than previously thought. Two of the recent 
studies that used the ADNI cohort (Byun et al., 2015; Ferreira et al., 2017), found that 
the levels of CSF Aβ1-42  and  total tau were abnormal in the minimal atrophy subtype 
and in between the typical and the limbic-predominamt subtypes. These findings 
indicate that the minimal atrophy subtype is more likely to have Alzheimer’s disease 
etiology rather than depression or other psychiatric illnesses. The hippocampal-
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sparing presented higher scores on all the ADAS-Cog subtests (Table 2) compared to 
the minimal atrophy patients, indicating that they were more impaired in all cognitive 
domains. The fact that these differences did not reach statistical significance (apart 
from the constructional praxis) could be due to the unbalanced sample sizes (54 MA 
versus 17 HS subjects). 
Finally, in addition to the previous subtypes, in this study we also found two clusters 
of patients with diffuse brain atrophy. Although the two clusters had similar spatial 
patterns of atrophy, the diffuse 2 subtype presented greater frontal, parietal and 
temporal atrophy compared to the diffuse 1 subtype. Moreover, the diffuse 2 subtype 
performed significantly worse than the diffuse 1 both in general cognitive functions 
(CDR, MMSE) and memory (ADAS word recognition) as well as in orientation 
(ADAS orientation), praxis (ADAS ideational praxis) and language (ADAS following 
commands) components of the ADAS cognitive battery (Table 2).  
In this study, the comparison of demographic variables between groups showed that 
the limbic-predominant and diffuse subtypes were significantly older than the other 
subtypes. Hence, their patterns of brain atrophy might be characteristic of AD patients 
with a more advanced age. It is well known that age has an impact on medial temporal 
lobe structures and that elderly individuals present greater atrophy in hippocampal 
and temporal regions (Launer et al., 1994; Raz et al., 2004; Pereira et al., 2014). 
These findings are in line with the temporal atrophy observed in the limbic-
predominant AD patients in our study. These associations between increasing age and 
widespread volume losses in heteromodal association areas (Raji et al., 2009) could 
partially account for the severe brain atrophy we found in patients with diffuse 
atrophy subtypes, who were significantly older than patients from other groups. 
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Patients with the hippocampal-sparing subtype had a younger age at onset of AD. 
Several studies have shown that early onset AD is associated with gray matter atrophy 
in regions outside the medial temporal lobe (Frisoni et al., 2007; Shiino et al., 2008; 
Canu et al., 2012). These regions include the posterior and frontoparietal cortices and 
could be responsible for greater impairment in visuospatial or executive functions 
(van der Flier., 2011). There is also evidence showing that early onset AD might have 
a more aggressive disease course, showing a faster cognitive decline compared to the 
late onset cases (Van der Vlies, 2007). Our findings are in line with this notion since 
the hippocampal-sparing group showed a significant decline in visuospatial and 
memory functions after one year. The decline in visuospatial functions agrees with the 
widespread parietal atrophy these patients presented and the strong association that 
exists between the parietal cortex and visuospatial and visuoconstructional abilities 
(Cabeza and Nyberg, 2000). Previous studies using functional MRI (fMRI) have 
shown that memory not only relies on temporal brain areas but also the prefrontal 
cortex, which is important for episodic memory encoding and semantic retrieval 
(Cabeza and Nyberg, 2000). This region was atrophied in the hippocampal-sparing 
cases of our study, suggesting that it might be responsible for the memory decline 
they showed after one year.  
In this study we found that patients with diffuse atrophy presented lower scores on the 
MMSE compared to the other groups, indicating that widespread brain atrophy was 
associated with greater overall cognitive impairment. In addition, they also showed a 
significant decline in visuospatial, memory and executive functions after one year, 
suggesting that, similarly to the hippocampal-sparing subtype, they might be a more 
aggressive disease phenotype. Two recent studies (Varol et al., 2016; Dong et al., 
2017) also identified two diffuse atrophy subtypes, similarly to our study. 
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In a previous study, the ratio of hippocampus to cortex volumes provided a good 
discrimination between AD subtypes, suggesting it could be a good marker to assess 
AD heterogeneity (Whitwell et al., 2012). In our study, this ratio distinguished well 
the limbic-predominant, hippocampal-sparing and diffuse subtypes but not patients 
with the minimal atrophy subtype. This was because patients with minimal atrophy 
had the highest cortical volume, but their hippocampal volumes were lower than the 
hippocampal-sparing subtype. This is a numerical issue that arises from the ratio’s 
formula and is not connected with the progression of the subtypes or their similarity. 
Since the AD subtypes atrophy patterns were not linear, it was not possible to 
distinguish them well using the previous ratio. Multiple anatomical brain measures 
and their non-linear relationships are needed to separate well different AD subtypes. 
Regarding the supervised analysis, the precuneus, middle occipital and orbital gyri 
were the most important anatomical regions that helped discriminate clusters of 
patients (figure 4). The precuneus has been widely studied in AD and atrophy in this 
area has been associated with an early disease onset (Karas et al., 2007). The subtypes 
with the lowest precuneus volume were the hippocampal-sparing and the diffuse 2. 
The extent of atrophy in the hippocampal-sparing subtype can be explained by its 
onset, which is the earliest among the subtypes. As for the diffuse 2 subtype, the 
reason why the volume in this area was low is probably related to the severity of this 
subtype in contrast to the rest of the subtypes with respect to cortex volume (Figure 3, 
A).  The volumes of the middle occipital gyrus separated the minimal-atrophy subtype 
from the other two subtypes of this branch and the interpretation of this is 
straightforward, since the minimal atrophy group showed no atrophy in that region. 
The orbital gyrus was the cortical area that distinguished the hippocampal-sparing and 
diffuses 2 subtypes. The hippocampal-sparing does not show atrophy in limbic 
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regions, including the orbital gyrus, and therefore its discrimination from the diffuse 2 
subtype is feasible using this region.  
Our study has a few limitations. The cross-sectional design did not allow us to 
examine anatomical changes over time. CSF measurements were absent for more than 
50% of the sample; therefore we were not able to investigate the link between Aβ 
pathology and AD subtypes. The ROI approach in our analysis might have missed 
some subtle effects in cortical thinning. 
Our study also has several strengths. For instance, the application of the random forest 
method in the cluster analyses is an important advantage compared to previous studies 
since it takes into account both the high dimensionality and the non-linear 
relationships that exist between anatomical regions. The inclusion of both cortical and 
subcortical regions in our analysis is also a strength that allowed us to contrast better 
our results with previous neuropathological studies assessing AD subtypes, including 
the one called limbic-predominant, which is characterized by hippocampal atrophy. 
In conclusion, our study is the first to assess the patterns of cortical and subcortical 
atrophy in AD using two different cohorts in the same clustering analysis. Our 
findings suggest there is substantial heterogeneity among AD patients and that this 
heterogeneity has an important impact on how patients progress over time, even after 
a short follow-up period of one year. Future studies examining brain atrophy in AD 
should be aware that several subtypes of neurodegeneration might be present in their 
cohorts and that this can influence clinical presentation and prognosis. 
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Table 1. Differences between AD subtypes in subcortical volumes. 
 Minimal 
atrophy 
Limbic 
predominant 
Hippocampal 
sparing 
Diffuse 1 Diffuse 2 P-valuek 
Hippocampus a b d e g h j 6024 (969) 4566 (753) 5902 (846) 5252 (843) 5116 (772) <0.001 
Amygdala a b d e h 2299 (390) 1671 (386) 2134 (371) 1999 (372) 1962 (368) <0.001 
Thalamus b d e g h j 12380 (988) 11452 (1316) 12610 (982) 11980 (920) 11780 (885) 0.002 
Caudate 6967 (942) 6430 (984) 7054 (1220) 6862 (1135) 6854 (1195) 0.520 
Putamen b e h 9167 (1256) 7800 (1075) 8765 (1735) 8436 (1102) 8013 (1103) <0.001 
Accumbensb d e h j 749 (160) 547 (154) 703 (168) 648 (134) 595 (124) <0.001 
Palliduma b d h j 2778 (284) 2460 (258) 2911 (350) 2708 (322) 2611 (292) <0.001 
The data are presented as mean (sd). All results and corresponding p values were corrected by multiple comparisons (p < 0.05): 
a Significant differences between LP and D1   subtypes (p <0.05) 
b Significant differences between LP and MA subtypes (p <0.05) 
c
 Significant differences between LP and D2   subtypes (p <0.05) 
d Significant differences between LP and HS   subtypes (p <0.05) 
e Significant differences between D1 and MA subtypes (p <0.05) 
f Significant differences between D1 and D2   subtypes (p <0.05) 
g
 Significant differences between D1 and HS  subtypes (p <0.05) 
h Significant differences between MA and D2 subtypes (p <0.05) 
I  Significant differences between MA and HS subtypes (p <0.05) 
j  Significant differences between D2 and HS  subtypes (p <0.05) 
k
 Significant differences across all AD groups (p < 0.05) 
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Table 2. Demographic and clinical characteristics of controls and different AD subtypes.  
 Controls Minimal 
atrophy 
Limbic 
predomina
nt 
Hippocamp
al sparing 
Diffuse 1 
 
Diffuse 2  
 
P value 
N (%) 328 54 (18.1) 12 (4.0) 17 (5.7) 167 (55.8) 49 (16.4) - 
AddNeuroMed/ADNI N (%)  18/36  (15.8/19.5) 4/8 (3.5/4.3) 4/13 (3.5/7) 58/109 (50.8/58.9) 30/19 (26.3/10.3) - 
Women(%) 163 (49.7) 29 (54.0) 9 (75.0) 8 (47.0) 91 (54.5) 27 (55.1) 0.658 
Age b e h d g j 74.9 (71.5-78) 72.0 (68.8-76) 80.0 (76.5-
84) 
70.9 (64-77) 77.0 (71-80.3) 79.0 (75-82) <0.001 
Disease duration a b c - 3.00 (2-4.8) 4.50 (4.4-
7.0) 
4.00 (3-5) 3.00 (2-5) 2.60 (1.9-5) 0.073 
Age at the Onset e h g j - 69.5 (65-73) 75.0 (67.5-
79) 
67.0 (60-74) 73.0 (68-78) 75.0 (71-79) <0.001 
Education j 15.50 (12-18) 13.0 (8-16) 13.0 (9-
15.5) 
16.0 (10-18) 13.0 (10-16) 11.0 (5-15) 0.053 
ApoE e4 (%) 88 (26.0) 36 (66.0) 6 (50.0) 10 (58.8) 101 (60.5) 28 (57.1) 0.845 
MMSE  e f h 29.0 (29-30) 24.0 (23-26) 22.5 (21.5-
25) 
23.0 (21-24) 23.0 (21-25) 21.0 (18-23) <0.001 
CDR general b e f h j 0.00 (0.0) 0.71 (0.3) 0.96 (0.1) 0.82 (0.39) 0.90 (0.41) 1.11 (0.5) <0.001 
Word recall task e h 3.70 (1.3) 5.50 (1.4) 6.20 (1.8) 6.00(1.1) 6.50 (1.5) 6.75 (1.3) <0.001 
Naming objects and fingers - 0.40(0.7) 0.58 (0.7) 0.47 (0.8) 0.70(0.9) 0.73 (0.9) 0.140 
Following commands f h - 0.57 (0.7) 0.70(0.5) 0.90 (0.9) 0.80(1.0) 1.30(1.1) 0.004 
Constructional praxis h I - 0.70 (0.6) 0.75 (0.6) 1.50(1.0) 0.95 (0.8) 1.30(1.0) 0.005 
Ideational praxis f h - 0.26 (0.5) 0.75 (0.9) 0.94 (1.3) 0.50 (0.9) 1.10(1.0) <0.001 
Orientation total incorrect b e f h j - 1.80 (1.8) 3.33 (2.0) 1.10 (1.5) 2.62 (2.0) 3.60 (2.0) <0.001 
Word recognition task mean 
incorrect b e h 
- 5.00 (2.4) 7.75 (3.2) 5.70(2.9) 6.80 (3.1) 4.00(3.3) 0.001 
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All values correspond to the median followed by range, except CDR and ADAS, in which they correspond to mean followed by standard 
deviation. ApoE e4, apolipoprotein allele e4; MMSE, mini-mental state examination; CDR, clinical dementia rating scale; ADAS, Alzheimer’s 
disease assessment scale. P values were calculated using X2 or Kruskal-Wallis tests across AD groups. The statistical tests are corrected for 
multiple comparisons (Holmes-Sidak) in 5% significance level. The AddNeuroMed/ADNI percentages are corrected for cohort population 
number. 
a
 Significant differences between LP and D1  subtypes (p <0.05) 
b
 Significant differences between LP and MA subtypes (p <0.05) 
c
 Significant differences between LP and D2  subtypes (p <0.05) 
d
 Significant differences between LP and HS  subtypes (p <0.05) 
e Significant differences between D1 and MA subtypes (p <0.05) 
f
 Significant differences between D1 and D2  subtypes (p <0.05) 
g
 Significant differences between D1 and HS  subtypes (p <0.05) 
h
 Significant differences between MA and D2 subtypes (p <0.05) 
I
 Significant differences between MA and HS subtypes (p <0.05) 
j
 Significant differences between D2 and HS  subtypes (p <0.05) 
k
 Significant differences across all AD groups (p < 0.05) 
 
 
 
 
 
 
 
 
Recall of test instruction e f h - 0.24 (0.7) 0.50(1.0) 0.60(0.9) 0.66 (1.2) 1.10 (1.3) <0.001 
Spoken language ability h - 0.30(0.6) 0.40 (0.7) 0.35 (1.0) 0.50 (0.8) 0.70 (0.9) 0.040 
Word finding difficulty in 
spontaneous speech c h 
- 0.60 (0.7) 0.25 (0.5) 0.90(1.1) 0.90 (1.1) 1.10 (1.0) 0.003 
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Table 3. Longitudinal comparisons in neuropsychological tests in the different AD subtypes. 
  Minimal 
atrophy 
Limbic 
predominant 
Hippocampa
l sparing 
Diffuse 1 Diffuse 2 
Word recall task 5.35 (5,70) 6.37(6.59) 6.06 (6.92)* 6.40 (6.48) 6.38 (6.82) 
Naming objects and fingers 0.44 (0,32) 0.44 (0.66) 0.50 (0.41) 0.54 (0.76) 0.64 (0.91) 
Following commands 0.54 (0.98) 0.67 (1.11) 0.59 (1.04) 0.54 (0.96)* 0.74 (1.10) 
Constructional praxis 0.71 (0.60) 0.78 (1.11) 0.86 (1.04) 0.92 (1.06) 1.07 (1.11) 
Ideational praxis 0.22 (0.20) 0.78 (1.22) 0.82 (0.87) 0.41 (0.91)** 0.48 (1.05)*** 
Orientation total incorrect 1.51 (1.92) 3.67 (4.11) 1.82 (3.05)* 2.26 (3.38)*** 2.64 (3.81)*** 
Word recognition task mean incorrect  4.88 (5.54) 8.22 (8.66) 5.73 (7.41) 6.79 (7.44) 6.24 (7.35)* 
Recall of test instruction 0.27 (0.37) 0.33 (0.77) 0.36 (0.72) 0.41 (0.55) 0.76 (1.02) 
Spoken language ability 0.22 (0.44) 0.44 (0.33) 0.45 (0.63) 0.46 (0.75) 0.53 (1.00) 
Word finding difficulty in spontaneous 
speech 0.49 (0.69) 0.22 (0.88) 1.05 (1.41) 0.71 (1.00) 0.97 (1.37) 
Comprehension of spoken language 0.29 (0.31) 0.33 (0.66) 0.50 (0.59) 0.45 (0.72) 0.47 (0.74) 
The data are presented as mean on the baseline (mean on the 12 months follow up). The statistical tests are corrected for multiple comparisons 
(Holmes-Sidak) in 5% significance level. 
*Significant (<0.05), **Significant (<0.0005),*** Significant (<0.00005) 
For the follow up, a subsample of the original sample was available: MA=41 (76%), LP=9 (75%), HS=10 (59%), D1=121 (78%), D2=27 (55%). 
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Fig. 1. Cluster analysis visual results in AD patients. (A) 3D Multidimensional 
scaling representation of the similarity matrix. Dots represent AD subjects, the 
distance between them symbolizes how similar the subjects are with respect to their 
cortical and subcortical patterns and the color denotes the clusters obtained by the 
hierarchical clustering. (B) Hierarchical clustering tree result. The horizontal axis 
represents the distance in random forest similarity between AD subjects, while the 
different colors of the vertical color bar correspond to different subtypes: Minimal 
atrophy (green), limbic predominant (black), hippocampal-sparing (light blue), diffuse 
1 (red) and diffuse 2 (dark blue). 
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Fig. 2. Cortical volume patterns in different AD subtypes. Significant cortical 
volume loss in the minimal atrophy subtype (A), the limbic-predominant subtype (B), 
the hippocampal-sparing subtype (C), the diffuse 1 subtype (D) and the diffuse 2 
subtype (E) compared to the CN group. Higher values (red/yellow color) indicate 
stronger differences between groups, threshold at p=0.001. The color bar denotes 
− logp !"#$. 
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Fig. 3. Cortex, hippocampus and hippocampus to cortex volume ratio for the 
different AD subtypes and controls. For the five subtypes: 
(A) shows the boxplots of the cortex volume and is measured in mm& 
(B) shows the boxplots of hippocampal volume and is measured in mm& 
(C) shows the ratio hippocampus to cortex.  
The statistical differences of the cortex, hippocampus and hippocampus to cortex ratio 
between the subtypes are presented in the supplementary Table 3 
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Fig. 4. Supervised classification tree with the most important variables and the 
subtypes of the random forest clustering. The 10 most important variables with 
decreasing accuracy were used in the training of this classification tree. The algorithm 
of the tree only keeps the variables that help it classify the subtypes optimally. Each 
of the 10 terminal nodes represent how many subjects of each subtype belong there 
under the tree rules of the branch and is encoded as: ('(, ', '&, '), '*)⇾( limbic 
predominant, diffuse 1, minimal atrophy, diffuse 2, hippocampal-sparing). The 
brackets indicate the terminal where most cases from each subtype were classified. 
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Subtypes of Alzheimer's disease can be found with high-dimensional cluster analysis. 
Five distinct subtypes of Alzheimer's disease (AD) exhibit substantial heterogeneity.  
Heterogeneity in AD has an impact on how patients function and progress over time. 
